scholarly journals In search of measures to improve the detection of increased cardiometabolic risk in children using second-generation antipsychotic medications

2021 ◽  
pp. 1-7
Author(s):  
Kirsi Kakko ◽  
Päivi Keskinen ◽  
Leena Pihlakoski ◽  
Raili Salmelin ◽  
Kaija Puura
Keyword(s):  
Second Generation ◽  
Cardiometabolic Risk ◽  
Antipsychotic Medications ◽  
Second Generation Antipsychotic

Second-Generation Antipsychotic Medications in Children and Adolescents

2004 ◽  
Vol 14 (3) ◽  
pp. 372-394 ◽  
Author(s):  
Jennifer Cheng-Shannon ◽  
James J. McGough ◽  
Caroly Pataki ◽  
James T. McCracken
Keyword(s):  
Children And Adolescents ◽  
Second Generation ◽  
Antipsychotic Medications ◽  
Second Generation Antipsychotic

Effective Dosing and Dose Equivalency of Second-Generation Antipsychotic Medications

CNS Spectrums ◽  
2004 ◽  
Vol 9 (S9) ◽  
pp. 24-31 ◽  
Author(s):  
Peter F. Buckley
Keyword(s):  
Comparative Studies ◽  
Second Generation ◽  
Fixed Dose ◽  
Antipsychotic Medications ◽  
Current Thinking ◽  
Regulatory Guidelines ◽  
Second Generation Antipsychotic ◽  
Dosing Patterns

ABSTRACTDosing patterns with second-generation antipsychotic medications (SGAs) are dynamic, with some SGAs surpassing current recommendations while others are declining in dose since their initial regulatory guidelines. Pertinent recent studies and available pharmacoepidemiologic reports, information, and expert consenses are reviewed herein to illuminate current thinking on the topic of dosing with SGAs. There is a need for fixed-dose studies of each SGA. Additionally, dosing should be a primary consideration when designing and subsequently interpreting comparative studies between SGAs.

Sign in / Sign up

Export Citation Format

Share Document